Osteosarcoma – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Osteosarcoma – Pipeline Review, H1 2018’, provides an overview of the Osteosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Osteosarcoma

– The report reviews pipeline therapeutics for Osteosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Osteosarcoma therapeutics and enlists all their major and minor projects

– The report assesses Osteosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Osteosarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Osteosarcoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advenchen Laboratories LLC

Amgen Inc

AntiCancer Inc

APEIRON Biologics AG

Arrowhead Pharmaceuticals Inc

AVEO Pharmaceuticals Inc

Bayer AG

Bellicum Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celldex Therapeutics Inc

Cellestia Biotech AG

Cellmid Ltd

CorMedix Inc

Eisai Co Ltd

Eleison Pharmaceuticals LLC

Endocyte Inc

Exelixis Inc

Intezyne Technologies Inc

Ipsen SA

Isofol Medical AB

Jiangsu Hengrui Medicine Co Ltd

MacroGenics Inc

Mateon Therapeutics Inc

MD Biosciences GmbH

Merck & Co Inc

Merck KGaA

Nektar Therapeutics

Novartis AG

Oncolys BioPharma Inc

Ono Pharmaceutical Co Ltd

Pfizer Inc

Scancell Holdings Plc

Sorrento Therapeutics Inc

Teijin Pharma Ltd

Tyme Technologies Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Osteosarcoma Overview 6

Osteosarcoma Therapeutics Development 7

Osteosarcoma Therapeutics Assessment 17

Osteosarcoma Companies Involved in Therapeutics Development 29

Osteosarcoma Drug Profiles 46

Osteosarcoma Dormant Projects 407

Osteosarcoma Discontinued Products 409

Osteosarcoma Product Development Milestones 410

Appendix 414

List of Tables

List of Tables

Number of Products under Development for Osteosarcoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Osteosarcoma Pipeline by Advenchen Laboratories LLC, H1 2018

Osteosarcoma Pipeline by Amgen Inc, H1 2018

Osteosarcoma Pipeline by AntiCancer Inc, H1 2018

Osteosarcoma Pipeline by APEIRON Biologics AG, H1 2018

Osteosarcoma Pipeline by Arrowhead Pharmaceuticals Inc, H1 2018

Osteosarcoma Pipeline by AVEO Pharmaceuticals Inc, H1 2018

Osteosarcoma Pipeline by Bayer AG, H1 2018

Osteosarcoma Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Osteosarcoma Pipeline by Boehringer Ingelheim GmbH, H1 2018

Osteosarcoma Pipeline by Bristol-Myers Squibb Co, H1 2018

Osteosarcoma Pipeline by Celldex Therapeutics Inc, H1 2018

Osteosarcoma Pipeline by Cellestia Biotech AG, H1 2018

Osteosarcoma Pipeline by Cellmid Ltd, H1 2018

Osteosarcoma Pipeline by CorMedix Inc, H1 2018

Osteosarcoma Pipeline by Eisai Co Ltd, H1 2018

Osteosarcoma Pipeline by Eleison Pharmaceuticals LLC, H1 2018

Osteosarcoma Pipeline by Endocyte Inc, H1 2018

Osteosarcoma Pipeline by Exelixis Inc, H1 2018

Osteosarcoma Pipeline by Intezyne Technologies Inc, H1 2018

Osteosarcoma Pipeline by Ipsen SA, H1 2018

Osteosarcoma Pipeline by Isofol Medical AB, H1 2018

Osteosarcoma Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Osteosarcoma Pipeline by MacroGenics Inc, H1 2018

Osteosarcoma Pipeline by Mateon Therapeutics Inc, H1 2018

Osteosarcoma Pipeline by MD Biosciences GmbH, H1 2018

Osteosarcoma Pipeline by Merck & Co Inc, H1 2018

Osteosarcoma Pipeline by Merck KGaA, H1 2018

Osteosarcoma Pipeline by Nektar Therapeutics, H1 2018

Osteosarcoma Pipeline by Novartis AG, H1 2018

Osteosarcoma Pipeline by Oncolys BioPharma Inc, H1 2018

Osteosarcoma Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Osteosarcoma Pipeline by Pfizer Inc, H1 2018

Osteosarcoma Pipeline by Scancell Holdings Plc, H1 2018

Osteosarcoma Pipeline by Sorrento Therapeutics Inc, H1 2018

Osteosarcoma Pipeline by Teijin Pharma Ltd, H1 2018

Osteosarcoma Pipeline by Tyme Technologies Inc, H1 2018

Osteosarcoma Dormant Projects, H1 2018

Osteosarcoma Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Osteosarcoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports